Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Farmworkers can become ill due to toxic exposure in their work environments. Recommending specific restrictions, educating patients on protection strategies, and partnering with agribusiness owners and allied health workers can drive development of alternatives to agricultural practices with health risks.
AMA J Ethics. 2018;20(10):E932-940. doi:
10.1001/amajethics.2018.932.
Clinicians can practice disability humility by developing social understandings of disability. This can help clinicians improve communication and express respect for patients’ authority about their experiences.
AMA J Ethics. 2018;20(12):E1181-1187. doi:
10.1001/amajethics.2018.1181
Rachel Koch, MD, John G. Meara, MD, DMD, MBA, and Anji E. Wall, MD, PhD
Single-procedure interventions with minimal follow-up and clear quality-of-life gain are well suited for surgical mission trips. But not all risks and benefits are easily assessed.
AMA J Ethics. 2019;21(9):E729-734. doi:
10.1001/amajethics.2019.729.